ATX-304
phase 1Develop a peripherally restricted pan-AMPK activator to address metabolic disease and aging-related chronic diseases linked to dysfunctional metabolism, including MASLD and related metabolic indications.
Small-molecule AMPK activation / metabolic switching; Phase 1B clinical trial plus preclinical studies in MASLD, semaglutide combination, and cisplatin-induced acute kidney injury models.
Amplifier Therapeutics dosed the first patients in a Phase 1B clinical trial of ATX-304 and later announced presentation of preclinical ATX-304 plus semaglutide data at ENDO 2025.
Site-listed publications report that ATX-304 reduces oxidative stress and improves MASLD via metabolic switching, and alters cellular metabolism to protect against cisplatin-induced acute kidney injury. Public records also mention preclinical semaglutide-combination data.